Sökning: id:"swepub:oai:lup.lub.lu.se:6b3b1873-d506-41ee-bb11-40100c077fff" >
Ticagrelor versus C...
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
-
- Hiatt, William R (författare)
- University of Colorado
-
- Fowkes, F Gerry R (författare)
- University of Edinburgh
-
- Heizer, Gretchen (författare)
- Duke University
-
visa fler...
-
- Berger, Jeffrey S (författare)
- New York University
-
- Baumgartner, Iris (författare)
- University of Bern
-
- Held, Peter (författare)
- AstraZeneca, Sweden
-
- Katona, Brian G (författare)
- AstraZeneca, US
-
- Mahaffey, Kenneth W (författare)
- Stanford University
-
- Norgren, Lars (författare)
- Örebro University
-
- Jones, W Schuyler (författare)
- Duke University
-
Blomster, Juuso (författare)
-
Millegård, Marcus (författare)
-
Reist, Craig (författare)
-
Patel, Manesh R (författare)
-
- Gottsäter, Anders (creator_code:cre_t)
- Lund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups
-
visa färre...
-
(creator_code:org_t)
-
- 2017
- 2017
- Engelska.
-
Ingår i: The New England journal of medicine. - 0028-4793 .- 1533-4406. ; 376, s. 32-40
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin. We wanted to compare clopidogrel with ticagrelor, a potent antiplatelet agent, in patients with peripheral artery disease.METHODS: In this double-blind, event-driven trial, we randomly assigned 13,885 patients with symptomatic peripheral artery disease to receive monotherapy with ticagrelor (90 mg twice daily) or clopidogrel (75 mg once daily). Patients were eligible if they had an ankle-brachial index (ABI) of 0.80 or less or had undergone previous revascularization of the lower limbs. The primary efficacy end point was a composite of adjudicated cardiovascular death, myocardial infarction, or ischemic stroke. The primary safety end point was major bleeding. The median follow-up was 30 months.RESULTS: The median age of the patients was 66 years, and 72% were men; 43% were enrolled on the basis of the ABI and 57% on the basis of previous revascularization. The mean baseline ABI in all patients was 0.71, 76.6% of the patients had claudication, and 4.6% had critical limb ischemia. The primary efficacy end point occurred in 751 of 6930 patients (10.8%) receiving ticagrelor and in 740 of 6955 (10.6%) receiving clopidogrel (hazard ratio, 1.02; 95% confidence interval [CI], 0.92 to 1.13; P=0.65). In each group, acute limb ischemia occurred in 1.7% of the patients (hazard ratio, 1.03; 95% CI, 0.79 to 1.33; P=0.85) and major bleeding in 1.6% (hazard ratio, 1.10; 95% CI, 0.84 to 1.43; P=0.49).CONCLUSIONS: In patients with symptomatic peripheral artery disease, ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular events. Major bleeding occurred at similar rates among the patients in the two trial groups. (Funded by AstraZeneca; EUCLID ClinicalTrials.gov number, NCT01732822 .).
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Adenosine/adverse effects
- Aged
- Cardiovascular Diseases/mortality
- Clopidogrel
- Double-Blind Method
- Female
- Hemorrhage/chemically induced
- Humans
- Intermittent Claudication/drug therapy
- Ischemia/drug therapy
- Kaplan-Meier Estimate
- Leg/blood supply
- Male
- Middle Aged
- Peripheral Arterial Disease/drug therapy
- Platelet Aggregation Inhibitors/adverse effects
- Purinergic P2Y Receptor Antagonists/therapeutic use
- Ticagrelor
- Ticlopidine/adverse effects
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Hiatt, William R
-
Fowkes, F Gerry ...
-
Heizer, Gretchen
-
Berger, Jeffrey ...
-
Baumgartner, Iri ...
-
Held, Peter
-
visa fler...
-
Katona, Brian G
-
Mahaffey, Kennet ...
-
Norgren, Lars
-
Jones, W Schuyle ...
-
Blomster, Juuso
-
Millegård, Marcu ...
-
Reist, Craig
-
Patel, Manesh R
-
Gottsäter, Ander ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
The New England ...
- Av lärosätet
-
Lunds universitet
-
Uppsala universitet
-
Karolinska Institutet